Correlating immunological and magnetic resonance imaging markers of disease activity in multiple sclerosis

Journal of Neurology Neurosurgery and Psychiatry

Volumn 64, Issue SUPPL. 1, 1998, Pages

  Giovannoni, G ^a   Kieseier, B ^a   Hartung, H P ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Disease monitoring; Magnetic resonance imaging; Multiple sclerosis

Indexed keywords

IMMUNOGLOBULIN; MARKER;

CONFERENCE PAPER; DIAGNOSTIC VALUE; DISEASE ACTIVITY; HUMAN; IMMUNOLOGY; INFLAMMATION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL;

BRAIN; CHRONIC DISEASE; DISEASE PROGRESSION; HUMANS; IMMUNOLOGIC FACTORS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS;

EID: 0031778459     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (69)

1. Whitaker JN, McFarland HF, Rudge P, et al. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Multiple Sclerosis 1995;1:37-47.
2. Martin R, McFarland HF. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit Rev Clin Lab Sci 1995;32:121-82.
3. Nesbit GM, Forbes GS, Scheithauser BW, et al. Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology 1991;180:467-74.
4. Rodriguez M, Scheithauer BW, Forbes G, et al. Oligodendrocyte injury is an early event in lesions of multiple sclerosis. Mayo Clin Proc 1993;68:627-36.
5. Katz D, Taubenberger JK, Cannella B, et al. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993;34:661-9.
6. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989;112:1419-28.
7. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerised data processing of 349 patients. Brain 1980;103:281-300.
8. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993;116:117-34.
9. Filippi M, Horsfield MA, Tofts PS, et al. Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. Brain 1995;118:1601-12.
10. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol 1996;39:6-16.
11. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-11.
12. Thompson AJ, Kermpde AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62.
13. Kidd D, Thorpe JW, Kendall BE, et al. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;60:15-9.
14. Revesz T, Kidd D, Thompson AJ, et al. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 1994;117:759-65.
15. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39;285-94.
16. Hughes RA. Immunotherapy for multiple sclerosis. J Neurol Neurosurg Psychiatry 1994;57:3-6.
17. Giovannoni G, Hartung HP. The immunopathogenesis of multiple sclerosis and Guillain-Barré syndrome. Curr Opin Neurol 1996;9:165-77.
18. Miller DH. Magnetic resonance imaging of patients with isolated idiopathic optic neuritis, brainstem syndromes and myelopathy. In: Goodkin DE, Rudick RA, eds. Multiple sclerosis. Advances in clinical trial design, treatment and future perspectives. London: Springer, 1996:187-200.
19. McClean BN, Luxton RW, Thompson EJ. A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the log IgG-index. Brain 1990;113: 1269-89.
20. Fazekas F, Offenbacher H, Fuchs S, et al. Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology 1988;38:1822-5.
21. Miller DH, Barkhof F, Berry I, et al. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry 1991;54:683-8.
22. Lai M, Hodgson T, Gawne-Cain M, et al. A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;60:339-41.
23. Capra R, Marciano N, Vignolo LA, et al. Gadolinium-pentetic acid magnetic resonance imaging in patients with relapsing remitting multiple sclerosis. Arch Neurol 1992; 49:687-9.
24. Silver NC, Good CD, Barker GJ, et al. Sensitivity of contrast enhanced MRI in multiple sclerosis: effects of gadolinium dose, magnetisation transfer contrast and delayed imaging. Brain 1997;120:1149-61.
25. Newcombe J, Hawkins CP, Henderson CL, et al. Histopathology of multiple sclerosis lesions detected by magnetic resonance imaging in unfixed postmortem central nervous tissue. Brain 1991;114:1013-23.
26. Rieckmann P, Altenhofen B, Riegel A, et al. Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis. Ann Neurol 1997;41:326-33.
27. Cross AH, O'Mara T, Raine CS . Chronologic localization of myelin-reactive cells in the lesions of relapsing EAE: implications for the study of multiple sclerosis. Neurology 1993;43:1028-33.
28. Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol 1993;33: 480-9.
29. Thompson AJ, Miller D, Youl B, et al. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology 1992;42:60-3.
30. Wiebe S, Lee DH, Karlik SJ, et al. Serial cranial and spinal cord magnetic resonance imaging in multiple sclerosis. Ann Neurol 1992;32:643-50.
31. Thorpe JW, Kidd D, Moseley IF, et al. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology 1996; 46:373-8.
32. McDonald WI. The dynamics of multiple sclerosis. The Charcot lecture. J Neurol 1993;240:28-36.
33. Giovannoni G, Lai M, Thorpe J, et al. Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging. Neurology 1997;48:1557-65.
34. Allen IV. Pathology and its implications. In: Matthews WB, ed. McAlpine's multiple sclerosis. 2nd ed. Edinburgh: Churchill Livingstone, 1991:341-78.
35. Fishman R, ed. Cerebrospinal fluid in diseases of the nervous system, 2nd ed. Philadelphia: Saunders, 1992.
36. Thompson EJ. The CSF proteins: a biochemical approach. Amsterdam:Elsevier, 1988.
37. Cumings JN. The cerebrospinal fluid in diagnosis. BMJ 1954;i:449-56.
38. Arvidson NG, Gudbjornsson B, Elfman L, et al. Circadian rhythm of serum interleukin-6 in rheumatoid arthritis. Ann Rheum Dis 1994;53:521-4.
39. Auzéby A, Bogdan A, Krosi Z, et al. Time-dependence of urinary neopterin, a marker of cellular immune activity. Clin Chem 1988;34:1866-7.
40. van Walderveen MA, Barkhof F, Hommes OR, et al. Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/ short-TE (T1-weighted) spin-echo images. Neurology 1995;45:1684-90.
41. Truyen L, Van Waesberghe JHTM, Van Walderveen MAA, et al. Accumulation of hypointense lesions (black-holes) on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 1996;47: 1469-76.
42. Losseff NA, Wang L, Lai M, et al. Progressive cerebral atrophy in multiple sclerosis: a serial MRI study. Brain 1996;119:2009-20.
43. Kidd D, Thorpe JW, Kendall BE, et al. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;60:15-9.
44. Losseff NA, Webb SL, O'Riordan JI, et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996;119:701-8.
45. Gass A, Barker GJ, Kidd D, et al. Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol 1994;36:62-7.
46. Davie CA, Barker GJ, Webb S, et al. Persistent functional deficit in multiple-sclerosis and autosomal-dominant cerebellar-ataxia is associated with axon loss. Brain 1995;118:1583-92.
47. Giovannoni G, Lai M, Kidd D, et al. Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis Brain 1997;120:1-13.
48. Trotter JL, Van der Veen RC, Clifford DB, Serial studies of serum interleukin-2 in chronic progressive multiple sclerosis patients: occurrence of bursts and effect of cyclosporine. J Neuroimmunol 1990;28:9-14.
49. Bongioanni P, Meucci G. T-cell tumour necrosis factor-α receptor binding in patients with multiple sclerosis. Neurology 1997;48:826-31.
50. Giovannoni G, Heales SJR, Silver NC, et al. Raised serum nitrate and nitrite levels in patients with multiple sclerosis. J Neurol Sci 1997;145:77-81.
51. Lopez-Moratalla N, Gonzalez A, Aymerich MS, et al. Monocyte inducible nitric oxide synthase in multiple sclerosis: regulatory role of nitric oxide. Biology and Chemistry 1997:1:95-104.
52. Balashov KE, Smith DR, Khoury SJ, et al. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4(+) T cells via CD40 ligand. Proc Nad Acad Sci USA 1997;94:599-603.
53. Nicoletti F, Patti F, Cocuzza C, et al. Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis. J Neuroimmunol 1996;70:87-90.
54. Paolino E, Fainardi E, Ruppi P, et al. A prospective-study on the predictive value of CSF oligoclonal bands and MRI in acute isolated neurological syndromes for subsequent progression to multiple-sclerosis. J Neurol Neurosurg Psychiatry 1996;60:572-5.
55. Rolak LA, Beck RW, Paty DW, et al. Cerebrospinal-fluid in acute optic neuritis-experience of the optic neuritis treatment trial. Neurology 1996;46:368-72
56. Sharief MK, Thompson EJ. The predictive value of intrathecal irnmunoglobulin-synthesis and magnetic-resonance-imaging in acute isolated syndromes for subsequent development of multiple-sclerosis. Ann Neurol 1991;29:147-51
57. Söderstrom M. The clinical and paraclinical profile of optic neuritis - a prospective-study. Ital J Neuroi Sci 1995;16:167-76.
58. Calabresi PA, Tranquill LR, Dambrosia JM, et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon β-1b. Ann Neurol 1997;41:669-74.
59. Trojano M, Avolio C, Simone IL, et al. Soluble intercellular-adhesion molecule-1 in serum and cerebrospinal-fluid of clinically active relapsing-remitting multiple-sclerosis - correlation with gd-dtpa magnetic-resonance-imaging enhancement and cerebrospinal-fluid findings. Neurology 1996;47:1535-41.
60. Mößner R, Fassbender K, Kuhnen J, et al. Circulating L-selectin in multiple-sclerosis patients with active, gadolinium-enhancing brain plaques. J Neuroimmunol 1996;65:61-5.
61. Mößner R, Fassbender K, Kuhnen J, et al. Vascular cell-adhesion molecule - a new approach to detect endothelial-cell activation in MS and encephalitis in-vivo. Acta Neurol Scand 1996;93:118-22.
62. Giovannoni G, Thorpe JW, Kidd D, et al. Soluble e-selectin in multiple-sclerosis-raised concentrations in patients with primary progressive disease. J Neurol Neurosurg Psychiatry 1996;60:20-6.
63. Hartung HP, Reiners K, Archelos JJ, et al. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis - correlation with magnetic resonance imaging. Ann Neurol 1995;38:186-93.
64. Rieckmann P, Albrecht M, Kitze B, et al. Tumour necrosis factor-a messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 1995;37:82-8.
65. Zoukos Y, Kidd D, Woodroofe MN, et al. Increased expression of high-affinity IL-2 receptors and β-adrenoceptors on peripheral blood mononuclear cells is associated with clinical and MRI activity in multiple sclerosis. Brain 1994;117:307-15.
66. Whitaker JN, Williams PH, Layton BA, et al. Correlation of clinical features and findings on cranial magnetic resonance imaging with urinary myelin basic protein-like material in patients with multiple sclerosis. Ann Neurol 1994;35:577-85.
67. Constantinescu CS, Mehta PD, Rostami AM. Urinary free kappa-light-chain levels in chronic progressive multiple sclerosis. Pathobiohgy 1994;62:29-33.
68. Hartung HP, Michels M, Reiners K, et al. Soluble ICAM-1 serum levels in multiple sclerosis and viral encephalitis. Neurology 1993;43:2331-5.
69. Voltz R, Hartmann M, Spuler S, et al. Multiple sclerosis: longitudinal measurement of interleukin-1 receptor antagonist. J Neurol Neurosurg Psychiatry 1997;62:200-1.